DOAC Therapy Works Well in Routine Care, but Complex Patients Expose Its Limits
Direct oral anticoagulants changed everyday anticoagulation by reducing the need for routine laboratory monitoring and simplifying long-term treatment compared with vitamin K antagonists. Their fixed dosing, predictable pharmacokinetics, and lower intracranial bleeding risk in many settings made them the preferred option for a broad range of thromboembolic disorders. Yet the convenience that defines DOAC therapy in standard practice becomes less reassuring when physiology is no longer standard. Renal dysfunction, hepatic impairment, extreme body weight, active cancer, and antiphospholipid syndrome each alter the balance between thrombosis and hemorrhage in ways that are not fully captured by the usual dosing schema.
The review published in 2025 in Journal of Clinical Medicine frames that problem clearly: DOACs are effective, but not universally interchangeable across complex clinical scenarios. The practical question is not whether these agents work in general. It is where the pharmacology remains dependable, and where the evidence becomes too thin to support blind extrapolation.
Renal and Hepatic Dysfunction Shift the Risk Equation
Renal impairment is one of the most consequential settings for DOAC decision-making because impaired clearance can increase drug exposure and amplify bleeding risk. Several DOACs depend, to varying degrees, on renal elimination, so declining kidney function can turn a fixed-dose regimen into an unstable exposure profile. In patients with advanced kidney disease, clinicians must weigh whether anticoagulation benefit still outweighs the danger of accumulation, especially when bleeding can be catastrophic and difficult to reverse in real time.
Hepatic dysfunction creates a different problem. The liver is central to drug metabolism and also to coagulation factor production, which means liver disease can simultaneously raise bleeding risk and promote thrombosis. In that setting, anticoagulant choice is rarely straightforward. The review emphasizes the need for individualized assessment because the same abnormal laboratory profile may reflect both impaired metabolism and a prothrombotic cirrhotic state. A single dosing rule cannot safely cover all degrees of hepatic injury.
The clinical consequence is immediate. Patients with combined renal and hepatic dysfunction sit at the far edge of the DOAC evidence base, where small pharmacokinetic shifts can have outsized bedside effects.
Obesity Raises Dosing Questions That Are Hard to Ignore
Obesity introduces uncertainty through altered volume of distribution, changes in drug absorption, and potential effects on metabolism and clearance. These changes may blunt or distort the exposure-response relationship that supports standard DOAC dosing in average-weight adults. In practical terms, the concern is not abstract underdosing alone; it is the possibility that a regimen validated in one body habitus may not deliver the same anticoagulant intensity in another.
That concern matters most when the clinical stakes are high, such as in the early treatment phase after venous thromboembolism or in patients who already carry multiple thrombotic risk factors. The review treats obesity as a setting where evidence remains incomplete enough to justify caution rather than routine reassurance. Clinicians are left to consider whether standard fixed doses achieve therapeutic reliability in very high body mass, or whether alternative strategies are needed in selected patients.
Cancer-Associated Thrombosis Demands More Than a One-Size-Fits-All Agent
Cancer-associated thrombosis is driven by multiple procoagulant mechanisms, including tumor-related inflammation, endothelial activation, and treatment-related vascular injury. This is not the same biologic state as a provoked venous thromboembolism in an otherwise healthy patient. The thrombotic burden is often persistent, and the bleeding risk may be elevated by mucosal tumors, thrombocytopenia, surgery, or concurrent chemotherapy.
DOACs have an important role in this setting, but the review makes clear that selection must be individualized. A patient with gastrointestinal or genitourinary malignancy may face a different bleeding profile than someone with a solid tumor elsewhere, and the interaction between anticoagulation and anticancer therapy can further complicate management. The appeal of oral administration is real, especially for long-term outpatient care, but convenience cannot substitute for careful risk stratification.
Cancer changes the coagulation system at the level of biology, not just logistics. Any anticoagulant decision has to account for that persistent inflammatory and prothrombotic drive.
Antiphospholipid Syndrome Remains a Problematic Use Case
Among the most cautionary scenarios discussed in the review is antiphospholipid syndrome. In this autoimmune disorder, the concern is recurrent thrombosis despite anticoagulation, and the available evidence has not established DOACs as a dependable universal substitute for vitamin K antagonists. The pathophysiology matters here: antiphospholipid antibodies create a highly thrombogenic milieu, and recurrence risk may remain substantial even when therapy appears pharmacologically adequate.
Because the review reporting ongoing controversy, DOAC use in antiphospholipid syndrome should be approached as an exception requiring careful judgment rather than a default choice. Patients with recurrent events, high-risk antibody profiles, or prior arterial thrombosis are especially vulnerable to treatment failure. In a disorder defined by thrombosis recurrence, the margin for error is narrow.
Rare Thrombotic Syndromes Leave Clinicians With Sparse Evidence
The article also addresses less common thromboses, including superficial venous thrombosis, embolic stroke of undetermined source, upper extremity vein thrombosis, inferior vena cava thrombosis, pelvic vein thrombosis, and cerebral vein thrombosis. These syndromes differ in anatomy, natural history, and recurrence risk, yet they are often managed under the pressure of limited trial data. DOACs are increasingly considered in these contexts, but evidence remains scarce in several of them.
Cerebral venous thrombosis and inferior vena cava thrombosis are particularly difficult because the clinical consequences can be severe while randomized evidence is limited. In pelvic and upper extremity thrombosis, treatment decisions often depend on provoking factors, symptom burden, and extension risk rather than on a definitive evidence hierarchy. The review does not present these disorders as solved problems. It presents them as places where extrapolation may be reasonable in selected patients, but only if the clinician understands how thin the supporting data can be.
Practical Anticoagulation Still Depends on Matching Drug to Physiology
The central message of the review is straightforward: DOACs are highly useful, but their value depends on the physiologic context in which they are prescribed. Fixed dosing is a strength only when absorption, clearance, and coagulation biology behave predictably. In renal failure, hepatic impairment, obesity, cancer, and antiphospholipid syndrome, that predictability can break down.
For clinicians, the useful habit is not automatic DOAC adoption and not reflexive avoidance. It is deliberate matching of the anticoagulant to the patient’s biology, bleeding risk, thrombotic mechanism, and the strength of the evidence in that specific scenario. Where data are robust, DOACs remain an efficient and often safer alternative to vitamin K antagonists. Where data are sparse or conflicting, the review supports a more cautious posture, especially when recurrent thrombosis or drug accumulation could change outcomes quickly at the bedside.
The remaining challenge is not whether DOACs belong in modern anticoagulation. It is deciding, patient by patient, where the evidence is strong enough to trust them and where the pharmacology still asks for restraint.